Biopharma & Life Sciences
IDEAYA Biosciences Executive Compensation (FY25)
IDYA · Executive and director compensation, fiscal 2023 to 2025
Data as of September 7, 2026Latest filing (8-K): June 23, 2026
181 figures on this page: 178 cited to the filing that reported them, 3 calculated from figures it prints. See the citations
Total compensation for Yujiro Hata, President, Chief Executive Officer and Director, came to $9,512,640 in fiscal 2025, and Hata's total was 43.8% lower than the $16,930,872 reported for fiscal 2024. Meanwhile, for fiscal 2025, the company reported a chief executive pay ratio of 28.3:1, against median employee compensation of $335,731. Separately, for fiscal 2025, shareholders backed the say-on-pay proposal with 88.5% of votes cast for or against in favor at the meeting held June 16, 2026. Companies named in the disclosed peer group include Arcellx, Inc., Arvinas, Inc., Biohaven Ltd., BridgeBio Pharma, Inc. and Celldex Therapeutics, Inc., among others.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Yujiro Hata: $16,930,872 → $9,512,640 (43.8% lower)
Say-on-pay support: 77.8% → 88.5% (10.7 points higher)
CEO pay ratio: 36:1 → 28.3:1 (21.4% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is IDEAYA Biosciences' chief executive and what were they paid?
Total compensation for Yujiro Hata, President, Chief Executive Officer and Director, came to $9,512,640 in fiscal 2025. Hata's total was 43.8% lower than the $16,930,872 reported for fiscal 2024.
What was IDEAYA Biosciences' say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 88.5% of votes cast for or against in favor at the meeting held June 16, 2026.
Which companies are in IDEAYA Biosciences' peer group?
Companies named in the disclosed peer group include Arcellx, Inc., Arvinas, Inc., Biohaven Ltd., BridgeBio Pharma, Inc. and Celldex Therapeutics, Inc., among others.
What is IDEAYA Biosciences' chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 28.3:1, against median employee compensation of $335,731.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Yujiro Hata President and Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Michael White Chief Scientific Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Darrin Beaupre Chief Medical Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Andres Ruiz Briseno Chief Accounting Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Yujiro Hata President and Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Darrin Beaupre Chief Medical Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Michael White Chief Scientific Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Andres Ruiz Briseno Chief Accounting Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Yujiro Hata President, Chief Executive Officer and Director | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Joshua Bleharski Chief Financial Officer | ◇ | ◇ | — | ◇ | ◇ | — | ◇ | ◇ |
Darrin Beaupre Chief Medical Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Michael White Chief Scientific Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Andres Ruiz Briseno Chief Accounting Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Douglas Snyder Chief Legal Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Andres Ruiz Briseno | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Darrin M. Beaupre | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Douglas B. Snyder | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Joshua Bleharski | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Michael A. White | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Yujiro S. Hata | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Andres Briseno | Option | ◇ | — | ◇ | 3/1/2034 |
| Option | ◇ | — | ◇ | 3/1/2032 | |
| Option | ◇ | — | ◇ | 2/24/2033 | |
| Option | ◇ | — | ◇ | 6/29/2033 | |
| Option | ◇ | — | ◇ | 2/27/2035 | |
| Michael White | Option | ◇ | — | ◇ | 3/1/2032 |
| Option | ◇ | — | ◇ | 2/27/2035 | |
| Option | ◇ | — | ◇ | 3/1/2034 | |
| Option | ◇ | — | ◇ | 2/24/2033 | |
| Douglas Snyder | Option | ◇ | — | ◇ | 2/27/2035 |
| Option | ◇ | — | ◇ | 9/26/2034 | |
| Yujiro Hata | Option | ◇ | — | ◇ | 3/1/2034 |
| Option | ◇ | — | ◇ | 3/1/2032 | |
| Option | ◇ | — | ◇ | 2/24/2033 | |
| Option | ◇ | — | ◇ | 2/27/2035 | |
| Darrin Beaupre | Option | ◇ | — | ◇ | 11/21/2032 |
| Option | ◇ | — | ◇ | 3/1/2034 | |
| Option | ◇ | — | ◇ | 2/24/2033 | |
| Option | ◇ | — | ◇ | 2/27/2035 | |
| Joshua Bleharski | Option | ◇ | — | ◇ | 5/29/2035 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Terry J. Rosen, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Scott W. Morrison | ◇ | — | ◇ | — | — | — | ◇ |
Jeffrey L. Stein, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Wendy L. Yarno | ◇ | — | ◇ | — | — | — | ◇ |
Catherine J. Mackey, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
M. Garret Hampton, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Susan L. Kelley, M.D | ◇ | — | ◇ | — | — | — | ◇ |
Yujiro S. Hata served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Arcellx, Inc. ACLX
- Arvinas, Inc. ARVN
- Biohaven Ltd. BHVN
- BridgeBio Pharma, Inc. BBIO
- Celldex Therapeutics, Inc. CLDX
- Cerevel Therapeutics Holdings, Inc. CERE
- Cogent Biosciences, Inc. COGT
- Crinetics Pharmaceuticals, Inc. CRNX
- CRISPR Therapeutics AG CRSP
- Denali Therapeutics, Inc. DNLI
- Immunovant, Inc. IMVT
- Kura Oncology, Inc. KURA
- Kymera Therapeutics, Inc. KYMR
- Morphic Holding, Inc. MORF
- Nuvalent, Inc. NUVL
- Protagonist Therapeutics, Inc. PTGX
- Relay Therapeutics, Inc. RLAY
- Revolution Medicines, Inc. RVMD
- Syndax Pharmaceuticals, Inc. SNDX
- Vaxcyte, Inc. PCVX
- Xencor, Inc. XNCR
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 16, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | June 24, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | May 31, 2024 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact IDEAYA Biosciences disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where IDEAYA Biosciences sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
181 figures on this page: 178 cited to the filing that reported them, 3 calculated from figures it prints.
178 cited to the filing
3 calculated from the filing
Documents cited
- 0001193125-26-279427
- 0001193125-26-1915012025 Director Compensation Table · DIRECTOR COMPENSATION · EXECUTIVE COMPENSATION TABLES & · Outstanding Equity Awards at Fiscal Year-End · and 1 more section
- 0001193125-25-145830
- 0000950170-25-060530Summary Compensation Table
- 0000950170-24-067407
- 0000950170-24-045724Summary Compensation Table
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “IDEAYA Biosciences executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/IDYA (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about IDEAYA Biosciences and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Peers IDEAYA Biosciences discloses
The companies named in IDYA's own disclosed peer group.
Terms on this page
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}